共 506 条
[1]
Bailey RA(2014)Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving global outcomes (KDIGO) staging BMC Res Notes 7 415-308
[2]
Wang Y(2013)Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 302-2128
[3]
Zhu V(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-334
[4]
Rupnow MF(2016)Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 375 323-657
[5]
Afkarian M(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-357
[6]
Sachs MC(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-39
[7]
Kestenbaum B(2019)SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet 393 31-2306
[8]
Hirsch IB(2019)Canagliflozin and renal outcomes in type 2 diabetes and nephropathy N Engl J Med 380 2295-33
[9]
Tuttle KR(2018)Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature Diabetes Obes Metab 20 25-2086
[10]
Himmelfarb J(2018)Development of SGLT1 and SGLT2 inhibitors Diabetologia 61 2079-477